Skip to main content
Clinical Trials/NCT01600638
NCT01600638
Completed
Not Applicable

Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature

Zeltiq Aesthetics1 site in 1 country25 target enrollmentMarch 29, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Body Fat Disorder
Sponsor
Zeltiq Aesthetics
Enrollment
25
Locations
1
Primary Endpoint
Safety of the Zeltiq System for Non-invasive Fat Reduction in Subjects With Greater Flank Curvature.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the ZELTIQ System and the CoolCurve+ applicator for non-invasive fat reduction in flanks for a patient population with sharp body curvature.

Detailed Description

The Zeltiq System with the CoolCurve+ applicator will be evaluated for safety and effectiveness in subjects with subcutaneous fat on the flanks and who have sharp body curvatures. The curvature of interest is typical of individuals who are relatively thin with a small body frame.

Registry
clinicaltrials.gov
Start Date
March 29, 2012
End Date
September 30, 2013
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Zeltiq Aesthetics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Safety of the Zeltiq System for Non-invasive Fat Reduction in Subjects With Greater Flank Curvature.

Time Frame: 8 weeks and 16 weeks post final treatment

Safety will be assessed by determination of the number of Unanticipated Adverse Device Effects (UADE) at the 8-week and 16-week post-treatment visits.

Change in Fat Layer Thickness When Compared to Untreated Control

Time Frame: 16 weeks post final treatment

Change in the fat layer thickness will be calculated by comparison of pre-treatment and 16 week post-treatment ultrasound measurements taken in the area treated with the device, and in the contralateral untreated control area. The Sponsor's standardized techniques for obtaining ultrasound imaging will be used. Overall fat layer thickness changes were normalized for each subject by subtracting the change in the untreated control from the change in treated area to remove the influence of weight variations. Results indicate the mm of fat layer reduction in the treated area.

Secondary Outcomes

  • Proportion of Pre-treatment Images Correctly Identified(16 weeks post final treatment)
  • Subject Satisfaction Questionnaire(16 weeks post final treatment)
  • Additional Safety Evaluation(Enrollment though 16 weeks post final treatment)

Study Sites (1)

Loading locations...

Similar Trials